NEW YORK (GenomeWeb) – GenePOC today announced it has received CE marking for its Revogene instrument and tests for Group B Streptococcus and Clostridium difficile for marketing in Europe and other geographies that recognize the designation.

The Quebec City-based rapid molecular devices firm, which is part of Debiopharm, added that it has completed clinical trials for GBS for the US Food and Drug Administration and expects to start clinical trials for C. difficile by mid-January.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.